Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients With Advanced Non-small Cell Lung Cancer.
Phase of Trial: Phase II
Latest Information Update: 16 Feb 2016
Price : $35 *
At a glance
- Drugs Gefitinib (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
- 11 Feb 2013 New trial record